Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-02-22
2011-02-22
Coleman, Brenda L (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S215000, C540S543000, C540S578000, C540S586000, C540S593000
Reexamination Certificate
active
07893051
ABSTRACT:
The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are thiophenyl and pyrrolyl azepine compounds. These compounds are serotonin receptor (5-HT2c) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT2c) is desired (e.g. addiction, anxiety, depression, obesity, and others).
REFERENCES:
patent: 4414225 (1983-11-01), Sauter et al.
patent: 2002/0123488 (2002-09-01), Binggeli et al.
patent: 2006/0003990 (2006-01-01), Bennani et al.
patent: 0 058 341 (1982-08-01), None
patent: 0 324 610 (1989-07-01), None
patent: 0 488 663 (1992-06-01), None
patent: 0224701 (2002-03-01), None
patent: 2006004931 (2006-01-01), None
STN printout of FREHEL et al., New Synthesis of 5,6,7,8-tetrahydro-4H-thieno[2,3-d]azepine, Journal of Heterocyclic Chemistry, vol. 22, No. 4, pp. 1011-1016, 1985.
J. A. Siuciak et al., “CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity”, Neuropharmacology 52 (2007) 279-290.
L. Zhou et al., “Serotonin 2C Receptor Agonists Improve Type 2 Diabetes via Melanocortin-4 Receptor Signaling Pathways”, Cell Metab, Nov. 7, 2007; 6(5): 398-405.
S. M. Grauer et al., “WAY-163909, a 5-HT2C agonist, enhances the preclinical potency of current antipsychotics”, Psychopharmacology (2009) 204: 37-48.
D. M. Tomkins et al., “An investigation of the role of 5-HT2C receptors in modifying ethanol self-administration behaviour”, Pharmacology, Biochemistry and Behavior 71 (2002) 735-744.
A. J. Grottick et al., “Studies to Investigate the Role of 5-HT2C Receptors on Cocaine- and Food-Maintained Behavior”, JPET (2000) vol. 295, No. 3: 1183-1191.
J. CG Halford, “Obesity drugs in clinical development” Current Opinion in Investigational Drugs (2006) 7(4): 312-318.
G. A. Higgins et al., “Serotonin and drug reward: focus on 5-HT2C receptors”, European Journal of Pharmacology 480 (2003) 151-162.
M. Isaac, “Serotonergic 5-HT2C Receptors as a Potential Therapeutic Target for the Design Antiepileptic Drugs”, Current Topics in Medicinal Chemistry (2005), 5: 59-67.
J. R. Martin et al., “5-HT2C Receptor Agonists: Pharmacological Characteristics and Therapeutic Potential”, JPET (1998) vol. 286, No. 2: 913-924.
K. J. Miller, “Serotonin 5-HT2C Receptor Agonists: Potential for the Treatment of Obesity”, Molecular Interventions Oct. 2005 vol. 5, Issue 5, 282-291.
Supplemental European Search Report for corresponding European Application No. EP 07 71 8077, Jul. 13, 2010.
Bennani Youssef L.
Bom David C.
Robarge Michael J.
Tumey L. Nathan
Athersys, Inc.
Coleman Brenda L
Wood Phillips Katz Clark & Mortimer
LandOfFree
Thiophenyl and pyrrolyl azepines as serotonin 5-HT 2c... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Thiophenyl and pyrrolyl azepines as serotonin 5-HT 2c..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thiophenyl and pyrrolyl azepines as serotonin 5-HT 2c... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2649709